* Clinical significance unknown

Indications and Usage

Sular^® is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Important Safety Information

The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of Sular^® in patients with heart failure has not been established. Sular^® should be administered cautiously in patients over the age of 65 and in those with severe hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of Sular^® is recommended. Sular^® should not be taken with grapefruit products.

Available in 8.5mg, 17mg,

25.5mg, and 34mg tablets

See Brief Summary on next page.

References: 1. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Therapeutica. 1996;22:23-35. 2. Punzi HA, Noveck R, Weiss RJ, et al. Are there differences in the effects of long-acting calcium antagonists on ambulatory blood pressure? Extended-release nisoldipine versus amlodipine as a model. Blood Press Monit. 1998;3:267-272.

Sular is a trademark of Sciele Pharma, Inc.